OCUL Ocular Therapeutix Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: OCUL

Price (delayed)

$5.87

Market cap

$872.44M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.01

Enterprise value

$758.26M

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation ...

Highlights
The equity has surged by 158% year-on-year
Ocular Therapeutix's quick ratio has surged by 65% QoQ and by 61% YoY
The debt has grown by 30% YoY
The net income has declined by 20% since the previous quarter and by 14% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ocutx.com
Peers: ANIK ZBH WST STE

Key stats

What are the main financial stats of OCUL
Market
Shares outstanding
148.63M
Market cap
$872.44M
Enterprise value
$758.26M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.12
Price to sales (P/S)
8.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.97
Earnings
Revenue
$58.44M
EBIT
-$69.4M
EBITDA
-$66.42M
Free cash flow
-$76.32M
Per share
EPS
-$1.01
Free cash flow per share
-$0.96
Book value per share
$1.15
Revenue per share
$0.73
TBVPS
$3.16
Balance sheet
Total assets
$252.06M
Total liabilities
$160.93M
Debt
$83.39M
Equity
$91.13M
Working capital
$197.34M
Liquidity
Debt to equity
0.92
Current ratio
6.66
Quick ratio
6.41
Net debt/EBITDA
1.72
Margins
EBITDA margin
-113.6%
Gross margin
91%
Net margin
-138.1%
Operating margin
-141%
Efficiency
Return on assets
-48.5%
Return on equity
-288.9%
Return on invested capital
-75%
Return on capital employed
-32%
Return on sales
-118.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

OCUL stock price

How has the Ocular Therapeutix stock price performed over time
Intraday
16.93%
1 week
39.76%
1 month
-30.78%
1 year
-1.68%
YTD
31.61%
QTD
-35.49%

Financial performance

How have Ocular Therapeutix's revenue and profit performed over time
Revenue
$58.44M
Gross profit
$53.16M
Operating income
-$82.38M
Net income
-$80.74M
Gross margin
91%
Net margin
-138.1%
The net income has declined by 20% since the previous quarter and by 14% year-on-year
The net margin has contracted by 19% from the previous quarter
Ocular Therapeutix's gross profit has increased by 13% YoY
The revenue has grown by 13% YoY

Growth

What is Ocular Therapeutix's growth rate over time

Valuation

What is Ocular Therapeutix stock price valuation
P/E
N/A
P/B
5.12
P/S
8.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.97
The company's EPS fell by 17% QoQ and by 10% YoY
The equity has surged by 158% year-on-year
OCUL's price to book (P/B) is 90% less than its last 4 quarters average of 51.8 and 80% less than its 5-year quarterly average of 25.7
The stock's P/S is 74% below its 5-year quarterly average of 30.4 but 25% above its last 4 quarters average of 6.4
The revenue has grown by 13% YoY

Efficiency

How efficient is Ocular Therapeutix business performance
Ocular Therapeutix's return on equity has shrunk by 131% YoY but it has increased by 40% QoQ
The company's return on sales fell by 18% QoQ but it rose by 4.5% YoY
OCUL's return on invested capital is up by 15% year-on-year but it is down by 12% since the previous quarter
The return on assets has declined by 14% year-on-year

Dividends

What is OCUL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for OCUL.

Financial health

How did Ocular Therapeutix financials performed over time
Ocular Therapeutix's total assets is 57% higher than its total liabilities
Ocular Therapeutix's total assets has surged by 69% YoY and by 55% QoQ
The current ratio has soared by 65% from the previous quarter and by 61% YoY
The debt is 8% less than the equity
The equity has surged by 158% year-on-year
The company's debt to equity has shrunk by 91% QoQ and by 49% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.